Sun Pharma Q1 preview: High domestic, global specialty biz growth to boost revenue

India’s largest drugmaker, which has posted steady mid-to-high single digit growth for the last eight consecutive quarters, is expected to see its revenues increasing 7-8% year-on-year in Q1FY26, according to brokerages Nuvama and Kotak Securities.